conv.

All stories
HealthQuiet 7d · day 11

Testosterone prescriptions for women surge 146%, hitting pharmacy denials

Women seeking off-label testosterone for menopause run into unexpected pharmacy rejections as prescribing rises sharply.

newest coverage 6d agosummary written 8d ago11 pieces4 likes & upvotes Google NewsNewswiresBlueskyHacker NewsMastodon

What to know

  • Testosterone prescriptions for women jumped 146% from early 2023 to mid-2026, driven by social media and FDA backing of hormone therapy generally, but no FDA-approved testosterone product exists for women.
  • Pharmacies including Amazon Pharmacy are newly rejecting or delaying prescriptions, citing safety and compliance concerns around customized doses, disrupting a previously accepted off-label practice.
  • Medical guidance supports testosterone only for low sexual desire in menopausal women; clinicians increasingly prescribing it off-label for fatigue and muscle loss lack evidence-based support from organizations like The Menopause Society.
  • The FDA will review evidence for testosterone in menopausal women at a public workshop, following promotion of the therapy by Health Secretary Kennedy and Defense Secretary Hegseth.

“Amazon Pharmacy said it does not dispense some testosterone prescriptions that require women to customize doses in order to ensure safe and compliant dispensing.”

Amazon Pharmacy, Company statement · Reuters ↗

Dr. Stephanie Faubion Director, Mayo Clinic Center for Women's HealthJennifer Lanoff Women's health nurse practitioner, Washington D.C.Robert F. Kennedy Jr.Robert F. Kennedy Jr. U.S. Health SecretaryPete HegsethPete Hegseth U.S. Defense SecretaryAmazon Pharmacy Pharmacy dispenser

Testosterone prescriptions for women surge 146%, hitting pharmacy denials
Investing.com News

How it unfolded 1 development · click the chart to see its coverage articlesposts

Peak 4 pieces in 3h at Sep 17, 5 AM; 11 pieces over 11 days (6 articles · 5 posts) Sep 13, 5 AM — 2 pieces · 2 articles — Google News 2Sep 13, 8 AM — quietSep 13, 11 AM — quietSep 13, 2 PM — quietSep 13, 5 PM — quietSep 13, 8 PM — quietSep 13, 11 PM — quietSep 14, 2 AM — quietSep 14, 5 AM — quietSep 14, 8 AM — quietSep 14, 11 AM — quietSep 14, 2 PM — quietSep 14, 5 PM — quietSep 14, 8 PM — quietSep 14, 11 PM — quietSep 15, 2 AM — quietSep 15, 5 AM — quietSep 15, 8 AM — 3 pieces · 3 articles — Newswires 2, Google News 1Sep 15, 11 AM — 1 piece · 1 post — Bluesky 1Sep 15, 2 PM — 1 piece · 1 post — Hacker News 1Sep 15, 5 PM — quietSep 15, 8 PM — quietSep 15, 11 PM — quietSep 16, 2 AM — quietSep 16, 5 AM — quietSep 16, 8 AM — quietSep 16, 11 AM — quietSep 16, 2 PM — quietSep 16, 5 PM — quietSep 16, 8 PM — quietSep 16, 11 PM — quietSep 17, 2 AM — quietSep 17, 5 AM — 4 pieces · 1 article · 3 posts — Mastodon 2, Google News 1, Bluesky 1Sep 17, 8 AM — quietSep 17, 11 AM — quietSep 17, 2 PM — quietSep 17, 5 PM — quietSep 17, 8 PM — quietSep 17, 11 PM — quietSep 18, 2 AM — quietSep 18, 5 AM — quietSep 18, 8 AM — quietSep 18, 11 AM — quietSep 18, 2 PM — quietSep 18, 5 PM — quietSep 18, 8 PM — quietSep 18, 11 PM — quietSep 19, 2 AM — quietSep 19, 5 AM — quietSep 19, 8 AM — quietSep 19, 11 AM — quietSep 19, 2 PM — quietSep 19, 5 PM — quietSep 19, 8 PM — quietSep 19, 11 PM — quietSep 20, 2 AM — quietSep 20, 5 AM — quietSep 20, 8 AM — quietSep 20, 11 AM — quietSep 20, 2 PM — quietSep 20, 5 PM — quietSep 20, 8 PM — quietSep 20, 11 PM — quietSep 21, 2 AM — quietSep 21, 5 AM — quietSep 21, 8 AM — quietSep 21, 11 AM — quietSep 21, 2 PM — quietSep 21, 5 PM — quietSep 21, 8 PM — quietSep 21, 11 PM — quietSep 22, 2 AM — quietSep 22, 5 AM — quietSep 22, 8 AM — quietSep 22, 11 AM — quietSep 22, 2 PM — quietSep 22, 5 PM — quietSep 22, 8 PM — quietSep 22, 11 PM — quietYesterday, 2 AM — quietYesterday, 5 AM — quietYesterday, 8 AM — quietYesterday, 11 AM — quietYesterday, 2 PM — quietYesterday, 5 PM — quietYesterday, 8 PM — quietYesterday, 11 PM — quietToday, 2 AM — quietToday, 5 AM — quiet 1
Sep 14Sep 15Sep 16Sep 17Sep 18Sep 19Sep 20Sep 21Sep 22now · 6:44 AM ET
  1. background

    FDA to hold public workshop on testosterone use in menopausal women — The U.S. Food and Drug Administration will convene a workshop Thursday to review evidence for testosterone use in menopausal women, a topic promoted by Health Secretary Robert F. Kennedy Jr. and Defense Secretary Pete Hegseth.

  2. 1
    “We've done (off-label testosterone prescriptions) forever. It's clinical guidelines recommended. Amazon has not given us a problem before. I don't know exactly what happened or why they rejected. They say it was a new policy.”
    — Jennifer Lanoff
    1. 4 outlets Testosterone scripts for women rise, along with denials and delays

      first by CNN, 7d ago · also Reuters, Investing.com News, Straits Times

    • CNN@c.im

      # CNN # News Testosterone scripts for women rise, along with denials and delays

      CNN@c.imMastodon7d agoview on Mastodon ↗
  3. background

    Testosterone prescriptions to women begin rising sharply — The rate of women receiving testosterone prescriptions jumps 146% between January 2023 and July 2026, according to data analysis by healthcare analytics firm Truveta.